David Rubin to Humans
This is a "connection" page, showing publications David Rubin has written about Humans.
Connection Strength
5.463
-
New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2026 Jan 01; 121(1):268-273.
Score: 0.030
-
Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):763-771.
Score: 0.030
-
A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease. Inflamm Bowel Dis. 2025 Aug 01; 31(8):2269-2285.
Score: 0.030
-
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey. Adv Ther. 2025 Sep; 42(9):4510-4526.
Score: 0.030
-
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1630-1636.
Score: 0.030
-
ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025 Jun 03; 120(6):1187-1224.
Score: 0.030
-
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. Dig Dis Sci. 2025 May; 70(5):1864-1872.
Score: 0.029
-
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience. Inflamm Bowel Dis. 2025 Mar 03; 31(3):746-750.
Score: 0.029
-
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study. Inflamm Bowel Dis. 2025 Feb 06; 31(2):432-441.
Score: 0.029
-
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
Score: 0.029
-
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025 01 04; 405(10472):33-49.
Score: 0.029
-
Artificial Intelligence in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am. 2025 Apr; 35(2):367-387.
Score: 0.029
-
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
Score: 0.029
-
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
Score: 0.029
-
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2025 Sep; 23(10):1817-1823.
Score: 0.029
-
Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays. Expert Rev Gastroenterol Hepatol. 2024 Oct; 18(10):587-596.
Score: 0.029
-
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
Score: 0.029
-
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflamm Bowel Dis. 2024 10 03; 30(10):1748-1758.
Score: 0.029
-
Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.
Score: 0.029
-
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
Score: 0.029
-
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 06 03; 30(6):939-949.
Score: 0.028
-
Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
Score: 0.028
-
Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 05 23; 30(Suppl 2):S1-S4.
Score: 0.028
-
Endoscopy in Inflammatory Bowel Disease: Indications, Timing, and Biopsy Protocol. Gastrointest Endosc Clin N Am. 2025 Jan; 35(1):1-18.
Score: 0.028
-
Optimizing treatment outcomes: integrating antihypertensive drug concentration measurement, personalized feedback, and psychosocial factors in resistant hypertension. J Hypertens. 2024 06 01; 42(6):1105-1106.
Score: 0.028
-
Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
Score: 0.028
-
The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1181-1185.
Score: 0.027
-
Amending the Pain Scale Used for Postoperative Pain Studies. JAMA Dermatol. 2024 02 01; 160(2):238-239.
Score: 0.027
-
Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2024 Feb; 26(2):31-40.
Score: 0.027
-
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
Score: 0.027
-
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.
Score: 0.027
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.027
-
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
Score: 0.027
-
At-home Disease Monitoring by Patient-performed Intestinal Ultrasound in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2023 12 05; 29(12):1997-1998.
Score: 0.027
-
Underinsurance Among Children With Special Health Care Needs in the United States. JAMA Netw Open. 2023 12 01; 6(12):e2348890.
Score: 0.027
-
Common Instances of Low-value Care in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2024 May; 22(5):923-932.
Score: 0.027
-
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
Score: 0.027
-
Perception of pacifier use among caregivers of infants 0-1?years of age. J Investig Med. 2023 12; 71(8):941-945.
Score: 0.027
-
(Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis. 2023 08 01; 29(8):1317-1326.
Score: 0.026
-
Association of In-person vs Virtual Education With Community COVID-19 Case Incidence Following School Reopenings in the First Year of the COVID-19 Pandemic. JAMA Netw Open. 2023 04 03; 6(4):e238300.
Score: 0.026
-
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
Score: 0.026
-
Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis. Inflamm Bowel Dis. 2023 02 01; 29(2):222-227.
Score: 0.026
-
Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 12; 10(10):1121-1128.
Score: 0.025
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
Score: 0.025
-
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
Score: 0.025
-
Endoscopic Management of Colitis-Associated Neoplasia. Gastrointest Endosc Clin N Am. 2022 Oct; 32(4):863-873.
Score: 0.025
-
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1386-1394.
Score: 0.025
-
Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. Inflamm Bowel Dis. 2022 09 01; 28(9):1465-1468.
Score: 0.025
-
O-Acylated Flavones in the Alpine Daisy Celmisia viscosa: Intraspecific Variation. J Nat Prod. 2022 08 26; 85(8):1904-1911.
Score: 0.025
-
Diagnostic and Management Considerations for the IPAA With Crohn's Disease-Like Features. Dis Colon Rectum. 2022 12 01; 65(S1):S77-S84.
Score: 0.025
-
Ileal Desmoid Tumor in Ileal Crohn's: Coincidence or Connection? Dig Dis Sci. 2023 03; 68(3):1071-1073.
Score: 0.024
-
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. Dig Dis Sci. 2023 02; 68(2):385-388.
Score: 0.024
-
IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
Score: 0.024
-
Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):369-379.
Score: 0.024
-
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
Score: 0.024
-
Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis. 2022 03 30; 28(4):553-559.
Score: 0.024
-
Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
Score: 0.024
-
Entering the Era of Disease Modification in Inflammatory Bowel Disease. Gastroenterology. 2022 04; 162(5):1367-1369.
Score: 0.024
-
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
Score: 0.023
-
International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
Score: 0.023
-
Yes, Children Can Transmit COVID, but We Need Not Fear. JAMA Pediatr. 2021 11 01; 175(11):1110-1112.
Score: 0.023
-
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
Score: 0.023
-
Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology. 2022 01; 162(1):331-333.e1.
Score: 0.023
-
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
Score: 0.023
-
Stratifying Risks of Ileal Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 07; 20(7):1620-1621.
Score: 0.023
-
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 10; 161(4):1118-1132.
Score: 0.023
-
SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 30; 70(30):1040-1043.
Score: 0.023
-
The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis. 2021 07 27; 27(8):1201-1209.
Score: 0.023
-
New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021 07 01; 37(4):357-363.
Score: 0.023
-
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflamm Bowel Dis. 2021 06 15; 27(7):1096-1106.
Score: 0.023
-
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
Score: 0.023
-
On the Value of COVID-19 Testing for Children Beyond the Spring of 2021. JAMA Netw Open. 2021 04 01; 4(4):e217850.
Score: 0.022
-
Using Wearable Biosensors to Predict Length of Stay for Patients with IBD After Bowel Surgery. Dig Dis Sci. 2022 03; 67(3):844-853.
Score: 0.022
-
Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
Score: 0.022
-
Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis. 2021 01 19; 27(2):203-206.
Score: 0.022
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.022
-
Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
Score: 0.022
-
A Tertiary Care-based Complex Care Program: Improving Care for Children With Medical Complexity. Med Care. 2020 11; 58(11):958-962.
Score: 0.022
-
Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
Score: 0.022
-
Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. Am J Gastroenterol. 2020 10; 115(10):1566-1569.
Score: 0.022
-
Quantitative Variable Assessment of Patellar Instability: An MRI-Based Study. AJR Am J Roentgenol. 2020 11; 215(5):1163-1170.
Score: 0.022
-
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
Score: 0.021
-
Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
Score: 0.021
-
Black Race and Public Insurance Are Predictive of Inappropriate Evaluation of Iron Deficiency Anemia and Diarrhea. Dig Dis Sci. 2021 07; 66(7):2200-2206.
Score: 0.021
-
Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. JAMA Netw Open. 2020 07 01; 3(7):e2016099.
Score: 0.021
-
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
Score: 0.021
-
Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology. 2020 Jul; 159(1):6-13.e6.
Score: 0.021
-
Re: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2247.
Score: 0.021
-
Periendoscopic code status. Gastrointest Endosc. 2020 02; 91(2):453.
Score: 0.021
-
Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020 05; 18(6):1346-1355.
Score: 0.021
-
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
Score: 0.021
-
Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol. 2020 10; 18(11):2518-2525.e1.
Score: 0.020
-
Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
Score: 0.020
-
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
Score: 0.020
-
Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
Score: 0.020
-
Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows. Inflamm Bowel Dis. 2019 08 20; 25(9):1443-1449.
Score: 0.020
-
Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
Score: 0.020
-
Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 05; 114(5):713-715.
Score: 0.020
-
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
Score: 0.020
-
Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
Score: 0.020
-
Discussion of Code Status in the Peri-Endoscopic Period. Am J Gastroenterol. 2019 03; 114(3):372-374.
Score: 0.019
-
ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
Score: 0.019
-
The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 2019 02 21; 25(3):427-435.
Score: 0.019
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.019
-
Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
Score: 0.019
-
Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2018 09 15; 24(10):2135-2141.
Score: 0.019
-
Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 04; 17(5):818-823.
Score: 0.019
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
Score: 0.019
-
[Nephrotic syndrome and microhematuria in a patient with nutcracker syndrome: Report of a case and review of the literature]. Internist (Berl). 2018 06; 59(6):608-614.
Score: 0.018
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.018
-
Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
Score: 0.018
-
Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. Aliment Pharmacol Ther. 2018 05; 47(10):1423-1424.
Score: 0.018
-
The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy. 2018 08; 10(10):837-849.
Score: 0.018
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.018
-
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
Score: 0.018
-
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
Score: 0.018
-
Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
Score: 0.018
-
Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
Score: 0.018
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
Score: 0.017
-
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
Score: 0.017
-
The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 04; 62(4):833-842.
Score: 0.017
-
Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
Score: 0.017
-
Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Curr Med Res Opin. 2017 May; 33(5):837-843.
Score: 0.017
-
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
Score: 0.017
-
The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
Score: 0.017
-
Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
Score: 0.017
-
Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
Score: 0.017
-
Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center. Gastrointest Endosc. 2016 12; 84(6):1078-1079.
Score: 0.017
-
Primary Rosai-Dorfman disease of the femur. Skeletal Radiol. 2017 Jan; 46(1):129-135.
Score: 0.017
-
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
Score: 0.016
-
Home Sweet Home? Will Medical Homes Be Coming to Your Neighborhood Sometime Soon? Inflamm Bowel Dis. 2016 08; 22(8):1981-3.
Score: 0.016
-
When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 11; 111(11):1508-1510.
Score: 0.016
-
Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
Score: 0.016
-
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
Score: 0.016
-
Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
Score: 0.016
-
Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep. 2016 Jan; 18(1):5.
Score: 0.016
-
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
Score: 0.015
-
U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm Bowel Dis. 2015 Sep; 21(9):2154-7.
Score: 0.015
-
Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
Score: 0.015
-
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul; 21(7):1709-18.
Score: 0.015
-
Hematochezia and a Mesenteric Mass. Gastroenterology. 2015 Jul; 149(1):e12-3.
Score: 0.015
-
Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. Am J Gastroenterol. 2015 Sep; 110(9):1252-6.
Score: 0.015
-
Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2015 Apr; 21(4):766-7.
Score: 0.015
-
The rationale and growth of advanced training in inflammatory bowel disease. Gastroenterology. 2015 Apr; 148(4):696-700.
Score: 0.015
-
Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
Score: 0.015
-
Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
Score: 0.014
-
Why it's time for updated U.S. colorectal cancer prevention guidelines in inflammatory bowel disease. Gastrointest Endosc. 2014 Nov; 80(5):849-51.
Score: 0.014
-
Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 12; 8(12):1569-81.
Score: 0.014
-
Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser. 2014; 79:101-14.
Score: 0.014
-
A rapid and accurate method to detect active small bowel gastrointestinal bleeding on video capsule endoscopy. Dig Dis Sci. 2014 Oct; 59(10):2503-7.
Score: 0.014
-
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
Score: 0.014
-
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
Score: 0.014
-
Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci. 2014 Jan; 59(1):6-8.
Score: 0.014
-
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
Score: 0.013
-
Initial experience of a through-the-scope balloon device for ileal intubation in Crohn's disease. Gastrointest Endosc. 2013 Oct; 78(4):669-70.
Score: 0.013
-
Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol. 2013 Oct; 108(10):1631-3.
Score: 0.013
-
Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci. 2013 Oct; 58(10):2748-50.
Score: 0.013
-
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
Score: 0.013
-
Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13.
Score: 0.013
-
What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):45-47.
Score: 0.013
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.013
-
Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
Score: 0.013
-
Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol. 2012 Dec; 107(12):1930-1.
Score: 0.013
-
In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3.
Score: 0.013
-
Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2.
Score: 0.013
-
Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4.
Score: 0.013
-
In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7.
Score: 0.012
-
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
Score: 0.012
-
Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
Score: 0.012
-
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21; 18(3):197-204.
Score: 0.012
-
Misreport of gestational weight gain (GWG) in birth certificate data. Matern Child Health J. 2012 Jan; 16(1):197-202.
Score: 0.012
-
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
Score: 0.012
-
Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci. 2012 Feb; 57(2):269-73.
Score: 0.012
-
Total abdominal colectomy for refractory ulcerative colitis. Surgical treatment in evolution. J Gastrointest Surg. 2011 Nov; 15(11):1909-16.
Score: 0.012
-
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
Score: 0.012
-
A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep; 27(9):1803-13.
Score: 0.011
-
Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84.
Score: 0.011
-
Dynamic neural networks supporting memory retrieval. Neuroimage. 2011 Jul 15; 57(2):608-16.
Score: 0.011
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.011
-
We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011 Jun; 9(6):456-7.
Score: 0.011
-
Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
Score: 0.011
-
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
Score: 0.011
-
The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience. Dig Dis Sci. 2010 Dec; 55(12):3495-501.
Score: 0.011
-
Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
Score: 0.011
-
What do Romanian children living in orphanages manifesting repetitive behaviors and American children in foster care with abnormal cortisol levels have in common? More than you would think. Arch Pediatr Adolesc Med. 2010 May; 164(5):492-3.
Score: 0.011
-
Performance of CT colonography in clinical trials. Gastrointest Endosc Clin N Am. 2010 Apr; 20(2):193-207.
Score: 0.010
-
Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010 Jan; 16(1):125-33.
Score: 0.010
-
Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am. 2009 Dec; 38(4):729-52.
Score: 0.010
-
Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci. 2009 Nov; 54(11):2473-83.
Score: 0.010
-
The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
Score: 0.010
-
Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
Score: 0.010
-
Levofloxacin-resistant-Streptococcus mitis endophthalmitis: a unique presentation of bacterial endocarditis. J Med Microbiol. 2009 Oct; 58(Pt 10):1385-1387.
Score: 0.010
-
Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):1979-85.
Score: 0.010
-
Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009 May; 15(5):750-5.
Score: 0.010
-
Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr; 15(4):581-8.
Score: 0.010
-
A rare case of granulocytic sarcoma in the mandible of a 4-year-old child: a case report and review of the literature. J Oral Maxillofac Surg. 2009 Feb; 67(2):410-6.
Score: 0.010
-
Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008 Oct; 42(9):1025-31.
Score: 0.009
-
An updated approach to dysplasia in IBD. J Gastrointest Surg. 2008 Dec; 12(12):2153-6.
Score: 0.009
-
Association between colorectal cancer and urologic cancers. Arch Intern Med. 2008 May 12; 168(9):1003-9.
Score: 0.009
-
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008 May 07; 14(17):2662-9.
Score: 0.009
-
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008 Feb; 14(2):265-74.
Score: 0.009
-
Corynebacterium bovis line related septicemia: a case report and review of the literature. Scand J Infect Dis. 2008; 40(6-7):575-7.
Score: 0.009
-
Medical professionalism and the doctor-patient relationship. Perspect Biol Med. 2008; 51(4):547-53.
Score: 0.009
-
p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
Score: 0.009
-
What is the most effective way to communicate results after endoscopy? Gastrointest Endosc. 2007 Jul; 66(1):108-12.
Score: 0.009
-
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
Score: 0.009
-
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
Score: 0.009
-
Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):229-33.
Score: 0.009
-
The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
Score: 0.008
-
Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1309-13.
Score: 0.008
-
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
Score: 0.008
-
Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging. 2007 Jan-Feb; 32(1):96-104.
Score: 0.008
-
Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):581-604.
Score: 0.008
-
Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun; 12(6):497-502.
Score: 0.008
-
The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology. 2006 Apr; 130(4):1350-2.
Score: 0.008
-
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials. J Crohns Colitis. 2025 Sep 28; 19(9).
Score: 0.008
-
Effect of gait retraining in minimalist footwear or barefoot on running footstrike and cadence: a systematic review. Res Sports Med. 2026 Mar-Apr; 34(2):163-175.
Score: 0.008
-
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):784-793.
Score: 0.008
-
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey. Curr Med Res Opin. 2025 Jun; 41(6):1017-1030.
Score: 0.008
-
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025 Jul 26; 406(10501):358-375.
Score: 0.008
-
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review. J Crohns Colitis. 2025 Jul 03; 19(7).
Score: 0.008
-
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. J Crohns Colitis. 2025 Jul 03; 19(7).
Score: 0.008
-
Appropriate Use and Complications of Corticosteroids in Inflammatory Bowel Disease: A Comprehensive Review. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2068-2082.
Score: 0.008
-
Histopathologic Evaluation and Single-cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2025; 19(10):101563.
Score: 0.008
-
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1583-1594.
Score: 0.008
-
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials. Lancet Gastroenterol Hepatol. 2025 Aug; 10(8):746-756.
Score: 0.008
-
Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects. Cell. 2025 Jul 24; 188(15):3927-3941.e13.
Score: 0.008
-
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
Score: 0.007
-
Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun; 100(6):1354-6.
Score: 0.007
-
Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
Score: 0.007
-
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 Nov; 169(6):1282-1293.
Score: 0.007
-
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
Score: 0.007
-
To test or "NOD-2" test: what are the questions? The balanced viewpoint. Inflamm Bowel Dis. 2005 May; 11(5):510-2.
Score: 0.007
-
Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun; 642(8067):458-466.
Score: 0.007
-
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nat Rev Gastroenterol Hepatol. 2025 Jun; 22(6):438-452.
Score: 0.007
-
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
Score: 0.007
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
Score: 0.007
-
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design. Lancet Gastroenterol Hepatol. 2025 06; 10(6):593-604.
Score: 0.007
-
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31; 12(1).
Score: 0.007
-
Exercise Therapies for Fibromyalgia Pain Catastrophizing: A Systematic Review and Comparative Analysis. Prim Care Companion CNS Disord. 2025 Mar 27; 27(2).
Score: 0.007
-
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. J Crohns Colitis. 2025 Mar 05; 19(3).
Score: 0.007
-
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflamm Bowel Dis. 2025 Mar 03; 31(3):647-654.
Score: 0.007
-
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review. Inflamm Bowel Dis. 2025 Mar 03; 31(3):812-842.
Score: 0.007
-
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study. Arthritis Care Res (Hoboken). 2025 Jun; 77(6):777-784.
Score: 0.007
-
Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. Nat Commun. 2025 Jan 21; 16(1):904.
Score: 0.007
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
Score: 0.007
-
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025 Oct 01; 120(10):2339-2349.
Score: 0.007
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
Score: 0.007
-
Point-of-Care Ultrasound in Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2025 Jul; 23(8):1277-1290.
Score: 0.007
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 03; 10(3):210-221.
Score: 0.007
-
Extensive Disease and Exposure to Multiple Biologics Precolectomy Is Associated with Endoscopic Cuffitis Post-Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2025 01 06; 31(1):72-76.
Score: 0.007
-
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2025 Oct 01; 120(10):2330-2338.
Score: 0.007
-
Role of antibiotics in the management of inflammatory bowel disease: a review. Rev Gastroenterol Disord. 2005; 5 Suppl 3:S10-5.
Score: 0.007
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.
Score: 0.007
-
Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024 11 04; 30(11):2195-2204.
Score: 0.007
-
Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives. J Crohns Colitis. 2024 Oct 15; 18(10):1726-1735.
Score: 0.007
-
Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat Med. 2024 Dec; 30(12):3555-3567.
Score: 0.007
-
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 09 26; 391(12):1119-1129.
Score: 0.007
-
Maternal gestational diabetes mellitus associates with altered gut microbiome composition and head circumference abnormalities in male offspring. Cell Host Microbe. 2024 Jul 10; 32(7):1192-1206.e5.
Score: 0.007
-
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus. Clin Gastroenterol Hepatol. 2025 May; 23(6):927-945.e2.
Score: 0.007
-
Development of Luminescent Biosensors for Calprotectin. ACS Chem Biol. 2024 06 21; 19(6):1250-1259.
Score: 0.007
-
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
Score: 0.007
-
Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care. Lancet. 2024 08 03; 404(10451):414-417.
Score: 0.007
-
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
Score: 0.007
-
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
Score: 0.007
-
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
Score: 0.007
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
Score: 0.007
-
Microbially catalyzed conjugation of GABA and tyramine to bile acids. J Bacteriol. 2024 01 25; 206(1):e0042623.
Score: 0.007
-
Implementing a Population-Based Social Determinants of Health Intervention: Early Lessons Learned from Collaboration between Clinical and Community Organizations. J Health Care Poor Underserved. 2024; 35(3):933-950.
Score: 0.007
-
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 02; 9(2):133-146.
Score: 0.007
-
Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol. BMJ Open Gastroenterol. 2023 12 11; 10(1).
Score: 0.007
-
Bile acid fitness determinants of a Bacteroides fragilis isolate from a human pouchitis patient. mBio. 2024 Jan 16; 15(1):e0283023.
Score: 0.007
-
A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index. J Crohns Colitis. 2023 Nov 24; 17(11):1733-1743.
Score: 0.007
-
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. J Crohns Colitis. 2023 Nov 24; 17(11):1761-1770.
Score: 0.007
-
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflamm Bowel Dis. 2023 11 02; 29(11):1723-1729.
Score: 0.007
-
Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2024 03; 22(3):611-620.e12.
Score: 0.007
-
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterol J. 2023 10; 11(8):797-806.
Score: 0.007
-
Crohn's Disease Features in Anastomotic Biopsies from Patients With and Without Crohn's Disease: Diagnostic and Prognostic Value. Mod Pathol. 2023 11; 36(11):100325.
Score: 0.007
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
Score: 0.007
-
Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
Score: 0.007
-
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 12; 165(6):1443-1457.
Score: 0.007
-
Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. Inflamm Bowel Dis. 2023 08 01; 29(8):1177-1190.
Score: 0.007
-
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 09; 8(9):853-859.
Score: 0.007
-
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
Score: 0.007
-
Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease. J Crohns Colitis. 2023 Jul 05; 17(7):1103-1113.
Score: 0.007
-
Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 06; 29(6):1520-1529.
Score: 0.007
-
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions. Am J Gastroenterol. 2023 11 01; 118(11):1940-1953.
Score: 0.007
-
Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
Score: 0.007
-
Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis. 2023 05 02; 29(5):695-704.
Score: 0.006
-
Metabolic independence drives gut microbial colonization and resilience in health and disease. Genome Biol. 2023 04 17; 24(1):78.
Score: 0.006
-
Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
Score: 0.006
-
Guide to Intestinal Ultrasound Credentialing, Documentation, and Billing for Gastroenterologists in the United States. Am J Gastroenterol. 2023 09 01; 118(9):1528-1531.
Score: 0.006
-
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2023 Mar 18; 17(2):199-210.
Score: 0.006
-
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflamm Bowel Dis. 2023 03 01; 29(3):417-422.
Score: 0.006
-
Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is It Ready for Standard Practice? Gastroenterology. 2023 05; 164(6):851-855.
Score: 0.006
-
Deep Learning Diagnosis and Classification of Rotator Cuff Tears on Shoulder MRI. Invest Radiol. 2023 06 01; 58(6):405-412.
Score: 0.006
-
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 01; 57(2):205-214.
Score: 0.006
-
Impact of High-Deductible Health Plans on Breast Reconstruction: Considerations for Financial Toxicity. Plast Reconstr Surg. 2023 02 01; 151(2):245-253.
Score: 0.006
-
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331.
Score: 0.006
-
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568.
Score: 0.006
-
Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.
Score: 0.006
-
Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2023 08; 21(9):2211-2221.
Score: 0.006
-
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 09; 7(9):871-893.
Score: 0.006
-
Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
Score: 0.006
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Score: 0.006
-
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
Score: 0.006
-
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
Score: 0.006
-
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022 07; 56(1):6-27.
Score: 0.006
-
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
Score: 0.006
-
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 07; 7(7):666-678.
Score: 0.006
-
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 11; 20(11):2427-2434.
Score: 0.006
-
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol. 2022 Feb 19; 22(1):71.
Score: 0.006
-
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1.
Score: 0.006
-
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
Score: 0.006
-
What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022 04; 162(5):1396-1408.
Score: 0.006
-
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261.
Score: 0.006
-
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2410-2418.
Score: 0.006
-
Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. J Rheumatol. 2022 03; 49(3):320-329.
Score: 0.006
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
Score: 0.006
-
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
Score: 0.006
-
Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
Score: 0.006
-
Dissemination of Gastroenterology and Hepatology Research on Social Media Platforms Is Associated With Increased Citation Count. Am J Gastroenterol. 2021 10 01; 116(10):2137-2139.
Score: 0.006
-
NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High-Quality Cancer Care. J Natl Compr Canc Netw. 2021 09 20; 19(9):1021-1026.
Score: 0.006
-
Using Quality Improvement and Technology to Improve Social Supports for Hospitalized Children. Hosp Pediatr. 2021 10; 11(10):1120-1129.
Score: 0.006
-
How to Navigate National Societal Organizations for Leadership Development and Academic Promotion: A Guide for Trainees and Young Faculty. Gastroenterology. 2021 11; 161(5):1361-1365.
Score: 0.006
-
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 12; 18(12):857-873.
Score: 0.006
-
Increasing Pediatric to Adult Healthcare Transition Services Through Clinical Decision Supports. J Pediatr Nurs. 2021 Nov-Dec; 61:292-297.
Score: 0.006
-
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
Score: 0.006
-
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
Score: 0.006
-
Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021 07 01; 37(4):313-319.
Score: 0.006
-
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
Score: 0.006
-
Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev Gastroenterol Hepatol. 2021 Sep; 15(9):985-997.
Score: 0.006
-
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
Score: 0.006
-
Lessons Learned: Developing an Online Training Program for Cultural Sensitivity in an Academic Psychiatry Department. Psychiatr Serv. 2021 10 01; 72(10):1233-1236.
Score: 0.006
-
Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425.
Score: 0.006
-
Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol. 2021 May 28; 27(20):2521-2530.
Score: 0.006
-
Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
Score: 0.006
-
Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021 05 17; 27(6):947-955.
Score: 0.006
-
Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflamm Bowel Dis. 2021 05 17; 27(6):836-847.
Score: 0.006
-
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021 05; 9(4):451-460.
Score: 0.006
-
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. J Manag Care Spec Pharm. 2021 Aug; 27(8):1086-1095.
Score: 0.006
-
Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Netw Open. 2021 04 01; 4(4):e216842.
Score: 0.006
-
Virtual colonoscopy: a novel imaging modality for colorectal cancer. Curr Oncol Rep. 2001 Mar; 3(2):88-93.
Score: 0.006
-
Variation in Payment per Work Relative Value Unit for Breast Reconstruction and Nonbreast Microsurgical Reconstruction: An All-Payer Claims Database Analysis. Plast Reconstr Surg. 2021 03 01; 147(3):505-513.
Score: 0.006
-
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583.
Score: 0.006
-
The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
Score: 0.006
-
How to Integrate a Medical Ethics Curriculum into Gastroenterology Fellowships. Gastroenterology. 2021 03; 160(4):1003-1006.
Score: 0.006
-
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr; 70(4):635-640.
Score: 0.006
-
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
Score: 0.006
-
Management of code status in the periendoscopic period: a national survey of current practices and beliefs of U.S. gastroenterologists. Gastrointest Endosc. 2021 07; 94(1):172-177.e2.
Score: 0.006
-
COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. Gastroenterology. 2021 04; 160(5):1447-1451.
Score: 0.006
-
Evaluation of COVID-19 Testing Strategies for Repopulating College and University Campuses: A Decision Tree Analysis. J Adolesc Health. 2021 01; 68(1):28-34.
Score: 0.005
-
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
Score: 0.005
-
Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
Score: 0.005
-
Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S774-S779.
Score: 0.005
-
Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology. 2021 02; 160(3):639-644.
Score: 0.005
-
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
Score: 0.005
-
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
Score: 0.005
-
Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. J Infect. 2020 11; 81(5):758-765.
Score: 0.005
-
Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
Score: 0.005
-
Restructuring Electrophysiology During the COVID-19 Pandemic: A Practical Guide From a New York City Hospital Network. Crit Pathw Cardiol. 2020 09; 19(3):105-111.
Score: 0.005
-
Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 04; 70(4):796-802.
Score: 0.005
-
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064.
Score: 0.005
-
An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
Score: 0.005
-
Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 11; 19(11):2333-2342.
Score: 0.005
-
Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
Score: 0.005
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.005
-
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
Score: 0.005
-
Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflamm Bowel Dis. 2020 06 18; 26(7):971-973.
Score: 0.005
-
Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc. 2020 Jul; 32(5):658-662.
Score: 0.005
-
Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020 07; 52(1):54-72.
Score: 0.005
-
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
Score: 0.005
-
Performance of electrophysiology procedures at an academic medical center amidst the 2020 coronavirus (COVID-19) pandemic. J Cardiovasc Electrophysiol. 2020 06; 31(6):1249-1254.
Score: 0.005
-
Policy and Practice Innovations to Improve Prescribing of Psychoactive Medications for Children. Psychiatr Serv. 2020 07 01; 71(7):706-712.
Score: 0.005
-
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
Score: 0.005
-
Impact of Physician Payments on Microvascular Breast Reconstruction: An All-Payer Claim Database Analysis. Plast Reconstr Surg. 2020 Feb; 145(2):333-339.
Score: 0.005
-
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
Score: 0.005
-
Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis. J Gastrointest Surg. 2020 11; 24(11):2637-2642.
Score: 0.005
-
Capsule Retention in Crohn's Disease: A Meta-analysis. Inflamm Bowel Dis. 2020 01 01; 26(1):33-42.
Score: 0.005
-
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
Score: 0.005
-
Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
Score: 0.005
-
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
Score: 0.005
-
IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
Score: 0.005
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.005
-
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
Score: 0.005
-
Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47.
Score: 0.005
-
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 Jul; 25(7):770-779.
Score: 0.005
-
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
Score: 0.005
-
Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
Score: 0.005
-
Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
Score: 0.005
-
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
Score: 0.005
-
Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 01; 53(1):e1-e11.
Score: 0.005
-
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
Score: 0.005
-
Legal Risks and Considerations Associated with Inflammatory Bowel Disease: A Primer. Am J Gastroenterol. 2018 11; 113(11):1577-1579.
Score: 0.005
-
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
Score: 0.005
-
The Influence of Physician Payments on the Method of Breast Reconstruction: A National Claims Analysis. Plast Reconstr Surg. 2018 10; 142(4):434e-442e.
Score: 0.005
-
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
Score: 0.005
-
Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
Score: 0.005
-
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
Score: 0.005
-
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
Score: 0.005
-
Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. J Crohns Colitis. 2018 Apr 27; 12(5):600-609.
Score: 0.005
-
The New Frontier: the Intestinal Microbiome and Surgery. J Gastrointest Surg. 2018 07; 22(7):1277-1285.
Score: 0.005
-
Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PLoS One. 2018; 13(4):e0193544.
Score: 0.005
-
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
Score: 0.005
-
Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
Score: 0.005
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.005
-
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
Score: 0.005
-
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 01; 11(10):1180-1199.
Score: 0.004
-
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
Score: 0.004
-
miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
Score: 0.004
-
Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):68-74.
Score: 0.004
-
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
Score: 0.004
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.004
-
miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clin Cancer Res. 2017 Sep 01; 23(17):5281-5291.
Score: 0.004
-
Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome. 2017 05 04; 5(1):50.
Score: 0.004
-
The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply. Acad Med. 2017 05; 92(5):703-708.
Score: 0.004
-
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
Score: 0.004
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
Score: 0.004
-
Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411.
Score: 0.004
-
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis. 2017 04; 23(4):494-501.
Score: 0.004
-
Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 03; 23(3):366-378.
Score: 0.004
-
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
Score: 0.004
-
Patient-Specific Bacteroides Genome Variants in Pouchitis. mBio. 2016 11 15; 7(6).
Score: 0.004
-
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
Score: 0.004
-
Home visiting and perinatal smoking: a mixed-methods exploration of cessation and harm reduction strategies. BMC Public Health. 2016 08 11; 16(1):764.
Score: 0.004
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
Score: 0.004
-
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
Score: 0.004
-
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
Score: 0.004
-
Activation of the Renin-Angiotensin System Promotes Colitis Development. Sci Rep. 2016 06 08; 6:27552.
Score: 0.004
-
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
Score: 0.004
-
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis. 2016 06; 22(6):1418-24.
Score: 0.004
-
Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
Score: 0.004
-
Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016 06 01; 310(11):G973-88.
Score: 0.004
-
Clostridium Difficile Infection in Ulcerative Colitis: Can Alteration of the Gut-associated Microbiome Contribute to Pouch Failure? Inflamm Bowel Dis. 2016 Apr; 22(4):902-11.
Score: 0.004
-
Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr; 22(4):940-7.
Score: 0.004
-
Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
Score: 0.004
-
Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2016 Jul; 84(1):87-95.e1.
Score: 0.004
-
Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut. 2017 02; 66(2):285-292.
Score: 0.004
-
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
Score: 0.004
-
Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
Score: 0.004
-
Deep enteroscopy with a conventional colonoscope: initial multicenter study by using a through-the-scope balloon catheter system. Gastrointest Endosc. 2015 Nov; 82(5):855-60.
Score: 0.004
-
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
Score: 0.004
-
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37.
Score: 0.004
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
Score: 0.004
-
Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014 Sep; 16(9):407.
Score: 0.004
-
Adverse childhood experiences of low-income urban youth. Pediatrics. 2014 Jul; 134(1):e13-20.
Score: 0.004
-
Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
Score: 0.003
-
Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
Score: 0.003
-
Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
Score: 0.003
-
A diagnosis that eats at you. Gastroenterology. 2013 Aug; 145(2):289, 489.
Score: 0.003
-
Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
Score: 0.003
-
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
Score: 0.003
-
Subdural hemorrhage in pediatric patients with enlargement of the subarachnoid spaces. J Neurosurg Pediatr. 2013 Apr; 11(4):438-44.
Score: 0.003
-
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
Score: 0.003
-
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54.
Score: 0.003
-
Screening for sleep disorders in pediatric primary care: are we there yet? Clin Pediatr (Phila). 2012 Dec; 51(12):1125-9.
Score: 0.003
-
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
Score: 0.003
-
Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med. 2012 Jun 05; 156(11):757-66, W-260.
Score: 0.003
-
Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012 Jun 05; 156(11):I-36.
Score: 0.003
-
Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
Score: 0.003
-
miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
Score: 0.003
-
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
Score: 0.003
-
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
Score: 0.003
-
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis. 2010 Oct; 16(10):1658-62.
Score: 0.003
-
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
Score: 0.003
-
Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts. NMR Biomed. 2009 Jul; 22(6):593-600.
Score: 0.002
-
Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
Score: 0.002
-
Israel-Gaza conflict. Lancet. 2009 Mar 14; 373(9667):891-2.
Score: 0.002
-
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
Score: 0.002
-
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
Score: 0.002
-
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
Score: 0.002
-
Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008 May; 67(6):902-9.
Score: 0.002
-
The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008 Jan; 14(1 Suppl A):s2-12; quiz s13-5.
Score: 0.002
-
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord. 2008; 8(1):21-30; quiz 31-2.
Score: 0.002
-
Prospective comparison of patient experience with colon imaging tests. Am J Med. 2006 Sep; 119(9):791-9.
Score: 0.002
-
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Gastroenterology. 2005 Aug; 129(2):770-2.
Score: 0.002
-
Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28; 365(9456):305-11.
Score: 0.002
-
Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
Score: 0.002
-
The case: can doctors say "enough"? Camb Q Healthc Ethics. 2003; 12(2):215-23.
Score: 0.002
-
Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics. 2002 Jul-Aug; 22(4):963-79.
Score: 0.002
-
Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology. 2002 Feb; 222(2):327-36.
Score: 0.001
-
The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 2002 Jan; 131(1):6-15.
Score: 0.001
-
Effects of billing and documentation requirements on the quantity and quality of teaching by attending physicians. Acad Med. 2001 Nov; 76(11):1144-7.
Score: 0.001
-
Treatment of anal fissures with topical nitroglycerin. Expert Opin Pharmacother. 2001 Jan; 2(1):41-5.
Score: 0.001
-
Malabsorption testing: a review. Curr Gastroenterol Rep. 2000 Oct; 2(5):370-7.
Score: 0.001
-
The Montefiore community children's project: a controlled study of cognitive and emotional problems of homeless mothers and children. J Urban Health. 1999 Mar; 76(1):39-50.
Score: 0.001
-
CT colonography with three-dimensional problem solving for detection of colonic polyps. AJR Am J Roentgenol. 1998 Oct; 171(4):989-95.
Score: 0.001
-
Ethics of a paired-kidney-exchange program. N Engl J Med. 1997 Jun 12; 336(24):1752-5.
Score: 0.001
-
Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996 Oct; 39(10):1073-80.
Score: 0.001
-
Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. J Magn Reson Imaging. 1995 Sep-Oct; 5(5):499-508.
Score: 0.001
-
Reduced cardiac selenium content in the acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec; 13(6):644-7.
Score: 0.001